Glucotrack, Inc. GCTK
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
2/9
Piotroski F — financial health
-73.93
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$19.4M | — | -$15.3M | $2.8M |
| 2024 | — | -$22.6M | — | -$12.6M | -$13.0M |
| 2023 | — | -$7.1M | — | — | $3.2M |
| 2022 | — | -$4.4M | — | -$3.7M | $1.2M |
| 2021 | — | -$4.1M | — | -$3.8M | $5.2M |
| 2020 | — | -$2.7M | — | -$3.6M | $9.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Malave Luis | director | 2025-10-03 | Grant | 463 | — |
| Carter Erin Catherine | director | 2025-10-03 | Grant | 386 | — |
| Balo Andrew K | director | 2025-10-03 | Grant | 1,285 | — |
| Malave Luis | director | 2025-07-11 | Grant | 1,200 | — |
| Carter Erin Catherine | director | 2025-07-11 | Grant | 1,000 | — |
| Balo Andrew K | director | 2025-07-11 | Grant | 3,332 | — |
| BALLANTYNE JOHN | director | 2025-03-26 | Grant | 4,126 | — |
| Malave Luis | director | 2025-03-26 | Grant | 2,076 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -73.93 (distress)
- Working capital / assets 0.369
- Retained earnings / assets -19.372
- EBIT / assets -2.053
- Equity / liabilities 0.564
Source: SEC EDGAR filings · CIK 0001506983 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.